It is well known that anti-TNFα therapy could lead to a myocardial infarction particularly in patients that are non-responders after six months of treatment supporting the idea that inflammation plays a crucial role in the onset of myocardial ischemia, although in some studies ADA had a decreased risk of incidence compared to csDMARDs [90,91]. This evidence concerns the gene TNF and myocardial ischemia.